Page 377 - The Toxicology of Fishes
P. 377

Liver Toxicity                                                              357


                       heart, ovary, testis, and gut (Suzuki et al., 2000). Flounder VDRβ expression was found to be weak in
                       liver, whereas VDRα was absent. In both species, the strong expression in the intestine and gut signifies
                       a putative role in regulation of intestinal metabolic activities.
                        The presence of a high-affinity VDR in the sea lamprey suggests that regulation of calcium is not a
                       critical function of ancestral VDR (Whitfield et al., 2003). Supporting this claim is the observation that
                       VDR expression precedes bone formation during Xenopus development (Li et al., 1997). Furthermore,
                       in mammals, VDRs mediate critical functions other than calcium and phosphate regulation, including
                       immune function, skin development, cell proliferation, and catabolism of endogenous and exogenous
                       substrates. The latter two are of particular importance in this consideration of liver toxicology. The fact
                       that lamprey VDR is capable of binding and transcriptional activation of mammalian CYP3A4 promoter
                       demonstrates conservation in the DNA binding behavior of an early form of this receptor and a possible
                       role in endobiotic and xenobiotic metabolism in the livers of fish (Whitfield et al., 2003). More functional
                       data are needed regarding the role of VDR in endobioitc and xenobiotic metabolism. Interesting, like
                       PXR, VDR contains a large insert between helices 1 and 3. While significantly different in sequence
                       than PXR, this insert may be associated with novel low-affinity ligand binding/transactivation activities
                       of VDR, specifically given the differing physical and nutritional environments between aquatic and
                       terrestrial species.

                       Peroxisome Proliferator-Activated Receptor (PPAR) in Fish
                       Peroxisome proliferator-activated receptors are ligand-dependent transcription factors belonging to the
                       NR1C subfamily of nuclear receptors. PPARs typically bind natural and synthetic fatty acids and certain
                       pharmaceutical ligands. More recently, however, it has been demonstrated that select members of the
                       PPAR subfamily bind environmental contaminants such as phthalate monoesters and organotins, making
                       them putative mechanistic targets for endocrine disruption (Grun and Blumberg, 2006; Hurst and Wax-
                       man, 2004). PPAR nuclear receptors exist in three forms: PPARα, PPARβ, and PPARγ. The ligand-
                       binding affinities for each form differ, as does the tissue-specific expression (Lee et al., 1995, 2003;
                       Schoonjans et al., 1996). In teleosts, all homologs of all three mammalian-defined PPAR isotypes (α, β,
                       and γ) have been identified in both marine and freshwater fish, although differences in total number of
                       PPAR genes (variants of the three isotypes) and their tissue distribution exist in comparison to mammals
                       (Andersen et al., 2000; Batista-Pinto et al., 2005; Ibabe et al., 2002; Leaver et al., 2005; Maglich et al.,
                       2003; Robinson-Rechavi and Laudet, 2001). From the molecular perspective, teleost PPARs heterodimer-
                       ize with RXR and bind to peroxisomal proliferator response element (PPRE)-like direct repeat elements
                       in promoter/enhancer regions, resulting in altered expression of target genes similar to that observed in
                       mammals (Leaver et al., 2005). Structurally, the N-terminal A/B domains of the PPARs are the least
                       conserved regions between fish and mammals; however, DNA-binding domains and ligand-binding
                       domains demonstrate a high degree of sequence identities among fish, amphibians, and mammals,
                       although the LBDs are generally longer in fish (Andersen et al., 2000; Leaver et al., 2005). PPARγ from
                       pufferfish, salmon, flounder, and flatfish are unique in that they contain key amino acid differences within
                       the ligand-binding domains, thus preventing the binding of acidic ligands. It has been suggested that
                       fatty acids are not likely to activate fish PPARγ (Leaver et al., 2005; Maglich et al., 2003). This represents
                       a significant difference between teleostean and mammalian forms of this receptor and is perhaps reflective
                       of early adaptations of the receptor to specific demands present in aquatic environments.
                        In mammals (rat and mouse), PPARα activation leads to peroxisome proliferation (number and volume)
                       and concurrent transcriptional activation of genes involved in lipid homeostasis. Genes involved in fatty
                       acid uptake and binding (fatty acid binding protein [FABP]), fatty acid ω-oxidation (acyl-CoA oxidase
                       [AOX]), lipoprotein assembly and transport (various apolipoproteins), and others are all modulated by
                       PPARα (Desvergne and Wahli, 1999; Hamadeh et al., 2002; Martin et al., 1997; Schoonjans et al., 1996;
                       Yadetie et al., 2003) and thus are excellent targets of investigation in fish model systems. Although some
                       studies have suggested that fish are refractory to peroxisome proliferation (Baldwin et al., 1993; Pretti
                       et al., 1999), in vivo and in vitro experiments show that many fish species are responsive to PPARα
                       ligands such as the fibrate-based pharmaceuticals and other natural peroxisome proliferators (Donohue
                       et al., 1993; Haasch et al., 1998; Ruyter et al., 1997; Scarano et al., 1994; Yang et al., 1990). More
   372   373   374   375   376   377   378   379   380   381   382